نتائج البحث - "Gaillard∗†, Stéphanie"

تحديد النتيجة رقم 1
1

دورية أكاديمية

Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.

المؤلفون: Gaillard, Stéphanie L.¹ (AUTHOR) stephanie.gaillard@jhmi.edu, Andreano, Kaitlyn J.¹ (AUTHOR), Gay, Laurie M.¹ (AUTHOR), Steiner, Meghan¹ (AUTHOR), Jorgensen, Matthew S.¹ (AUTHOR), Davidson, Brittany Anne¹ (AUTHOR), Havrilesky, Laura J.¹ (AUTHOR), Alvarez Secord, Angeles¹ (AUTHOR), Valea, Fidel A.¹ (AUTHOR), Colon-Otero, Gerardo¹ (AUTHOR), Zajchowski, Deborah A.¹ (AUTHOR), Chang, Ching-Yi¹ (AUTHOR), McDonnell, Donald P.¹ (AUTHOR), Berchuck, Andrew¹ (AUTHOR), Elvin, Julia A.¹ (AUTHOR)

المصدر: Gynecologic Oncology. Jul2019, Vol. 154 Issue 1, p199-206. 8p.

مصطلحات موضوعية: *GYNECOLOGIC cancer, *HORMONE therapy, *THERAPEUTICS, *ESTROGEN receptors, *AROMATASE inhibitors, *FALLOPIAN tubes

عرض رمز QR

أضف إلى السلة حذف من سلة الكتب
أضف إلى المفضلة

محفوظ في:
تحديد النتيجة رقم 2
2

دورية أكاديمية

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial.

المؤلفون: Liu, Joyce¹ (AUTHOR), Gaillard, Stéphanie² (AUTHOR), Hendrickson, Andrea Wahner³ (AUTHOR), Moroney, John⁴ (AUTHOR), Yeku, Oladapo⁵ (AUTHOR), Diver, Elisabeth⁶ (AUTHOR), Gunderson, Camille⁷ (AUTHOR), Arend, Rebecca⁸ (AUTHOR), Ratner, Elena⁹ (AUTHOR), Samnotra, Vivek¹⁰ (AUTHOR), Gupta, Divya¹⁰ (AUTHOR), Evilevitch, Lena¹⁰ (AUTHOR), Wang, Sarah¹⁰ (AUTHOR), Wang, Ping¹⁰ (AUTHOR), Tang, Joseph¹⁰ (AUTHOR), Bacque, Emeline¹⁰ (AUTHOR), Liu, Xiaohong¹⁰ (AUTHOR), Konecny, Gottfried¹¹ (AUTHOR)

المصدر: Gynecologic Oncology. 2021 Supplement 1, Vol. 162, pS17-S18. 2p.

مصطلحات موضوعية: *OVARIAN epithelial cancer, *OVARIAN cancer, *BEVACIZUMAB, *BIOMARKERS, *INTESTINAL perforation, *FALLOPIAN tubes

الشركة/الكيان: GLAXOSMITHKLINE

عرض رمز QR

أضف إلى السلة حذف من سلة الكتب
أضف إلى المفضلة

محفوظ في:
تحديد النتيجة رقم 3
3

دورية أكاديمية

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

المؤلفون: Shah, Payal D.^1,2 (AUTHOR), Wethington, Stephanie L.³ (AUTHOR), Pagan, Cheyenne⁴ (AUTHOR), Latif, Nawar⁴ (AUTHOR), Tanyi, Janos⁴ (AUTHOR), Martin, Lainie P.² (AUTHOR), Morgan, Mark⁴ (AUTHOR), Burger, Robert A.⁴ (AUTHOR), Haggerty, Ashley⁴ (AUTHOR), Zarrin, Haley⁴ (AUTHOR), Rodriguez, Diego⁴ (AUTHOR), Domchek, Susan^1,2 (AUTHOR), Drapkin, Ronny^1,4 (AUTHOR), Shih, Ie-Ming³ (AUTHOR), Smith, Simon A.⁵ (AUTHOR), Dean, Emma⁵ (AUTHOR), Gaillard, Stéphanie³ (AUTHOR), Armstrong, Deborah³ (AUTHOR), Torigian, Drew A.⁶ (AUTHOR), Hwang, Wei-Ting⁷ (AUTHOR)

المصدر: Gynecologic Oncology. Nov2021, Vol. 163 Issue 2, p246-253. 8p.

مصطلحات موضوعية: *OVARIAN epithelial cancer, *OLAPARIB, *POLY(ADP-ribose) polymerase, *ATAXIA telangiectasia, *DISEASE progression, *GYNECOLOGIC cancer

عرض رمز QR

أضف إلى السلة حذف من سلة الكتب
أضف إلى المفضلة

محفوظ في:

تنقيح النتائج